

SUPPLEMENTARY MATERIAL

A new flavonol derivative and other compounds from the leaves of *Bauhinia thonningii* Schum with activity against multidrug-resistant bacteria

Guy Raphael Sado Nouemsi^a, Jean-Bosco Jouda^b, Peron Bosco Leutcha^a, Valaire Yemene Matieta^c, Virginie Flaure Tsague Tankeu^a, Jenifer Reine Ngnouzouba Kuete^d, İlhami Çelik^e, Victor Kuete^c; Norbert Sewald^f, Alain Meli Lanang^{b,g,*}

ABSTRACT

The Investigation of the leaves of *Bauhinia thonningii* Schum led to the isolation and identification of a new flavonol derivative, 6-C-methylquercetin-3,4'-dimethyl ether (**1**) together with eleven known compounds including nine flavonoids (**2-10**), one pentacyclic triterpenoid (**11**) and one steroid glycoside (**12**). Their structures were established by extensive spectroscopic analyses, like 1D and 2D NMR, and HR-ESI-MS. The antibacterial activity of compound **1** as well as the reference antibiotic, ciprofloxacin was tested on Gram-negative multidrug-resistant bacteria overexpressing active efflux pumps, and against methicillin-resistant strains of *Staphylococcus aureus* (MRSA). Samples were tested alone and in combination with an efflux pump inhibitor (EPI), phenylalanine-arginine- β -naphthylamide (PABN). Results show that when compound **1** was tested alone, its inhibitor effects were obtained on 7/10 tested bacteria with the highest MIC value of 128 $\mu\text{g/mL}$ whilst in the presence of EPI, this activity significantly increase in all the 10 bacteria, with MIC ranging from 8-4 $\mu\text{g/mL}$. An interesting antibacterial activity was obtained with compound **1** against *Klebsiella pneumoniae* ATCC11296 (MIC of 4 $\mu\text{g/mL}$), KP55 and *Staphylococcus aureus* MRSA6 (MIC of 8 $\mu\text{g/mL}$) in the presence of the PABN.

Key words: *Bauhinia thonningii*, flavonoids, antibacterial activity.

* Corresponding Author: Alain Meli Lannang, PO Box 454 Ngaoundere, E-mail address: alainmeli@yahoo.com

Table of contents

Table S1: ^{13}C (150 MHz) and ^1H NMR (CD_3OD , 600 MHz) [J (Hz), δ (ppm)] data for compound **1**

Table S2. Minimal inhibitory concentrations (MIC) of compound **1** and ciprofloxacin alone and in the presence of an efflux pump inhibitor

Figure S1. UV of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S2. HRESI-MS (+) of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S3. ^1H -NMR spectrum (600 MHz, CD_3OD) of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S4. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S5. HSQC spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S6. HMBC spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S7. COSY ^1H - ^1H spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)

Figure S8. ^1H -NMR spectrum (600 MHz, CD_3OD) of compound **2**

Figure S9. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of compound **2**

Figure S10. ^1H -NMR spectrum (600 MHz, Acetone- d_6) of compound **3**

Figure S11. ^{13}C -NMR spectrum (150 MHz, Acetone- d_6) of compound **3**

Figure S12. ^1H -NMR spectrum (600 MHz, Acetone- d_6) of compound **4**

Figure S13. HMBC of compound **4**

Figure S14. ^1H -NMR spectrum (600 MHz, $\text{DMSO-}d_6$) of compound **5**

Figure S15. ^{13}C -NMR spectrum (150 MHz, $\text{DMSO-}d_6$) of compound **5**

Figure S16. ^1H -NMR spectrum (500 MHz, CD_3OD) of compound **6**

Figure S17. ^{13}C -NMR spectrum (125 MHz, CD_3OD) of compound **6**

Figure S18. ^1H -NMR spectrum (500 MHz, CD_3OD) of compound **7**

Figure S19. ^{13}C -NMR spectrum (125 MHz, CD_3OD) of compound **7**

Figure S20. ^1H -NMR spectrum (600 MHz, $\text{DMSO-}d_6$) of compound **8**

Figure S21. ^{13}C -NMR spectrum (150 MHz, $\text{DMSO-}d_6$) of compound **8**

Figure S22. ^1H -NMR spectrum (600 MHz, CD_3OD) of compound **9**

Figure S23. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of compound **9**

Figure S24. ^1H -NMR spectrum (600 MHz, Acetone- d_6) mixture of compounds **10** and **11**

Figure S25. ^{13}C -NMR spectrum (150 MHz, Acetone- d_6) mixture of compound **10a** and **11**

Figure S26. ^1H -NMR spectrum (600 MHz, Pyridine- d_5) of compound **12**

Figure S27. ^{13}C -NMR spectrum (150 MHz, Pyridine- d_5) of compound **12**

Figure S28. ^1H -NMR spectrum (600 MHz, DMSO- d_6) of compound **13**

Figure S29. ^{13}C -NMR spectrum (150 MHz, DMSO- d_6) of compound **13**

Figure S30. ^1H - ^1H COSY and HMBC correlations of compound **1**.

Table S1: ^{13}C (150 MHz) and ^1H NMR (CD_3OD , 600 MHz) [J (Hz), δ (ppm)] data for compound **1**

1		
Pos	δ_{C}	δ_{H} (nH, mult., J)
2	156.2	-
3	138.2	-
4	178.6	-
5	158.4	-
6	107.4	-
7	162.5	-
8	92.5	6.45 (1H, <i>s</i>)
9	154.8	-
10	104.4	-
1'	121.6	-
2'	111.5	7.70 (d, $J = 2.1$ Hz)
3'	147.5	-
4'	149.4	-
5'	115.2	6.96 (1H, d, $J = 8.4$ Hz)
6'	122.3	7.63 (1H, dd, $J = 8.4, 2.1$ Hz)
6-Me	6.4	2.09 (3H, <i>s</i>)
3-OMe	55.4	3.79 (3H, <i>s</i>)
4'-OMe	59.5	3.95 (3H, <i>s</i>)

Table S2. Minimal inhibitory concentrations (MIC) of compound **1** and ciprofloxacin alone and in the presence of an efflux pump inhibitor.

Bacterial strains	Samples, MIC values (in $\mu\text{g/mL}$) and fold increase of activity					
	1 alone	1+PA β N	Fold increase	CIP alone	CIP+PA β N	Fold increase
<i>Escherichia coli</i>						
ATCC10356	128	64	2	8	8	1
AG102	>128	64	>2	128	2	64
<i>Klebsiella pneumoniae</i>						
ATCC11296	32	4	8	64	2	32
KP55	64	8	8	16	1	16
<i>Pseudomonas aeruginosa</i>						
PA124	>128	32	>4	64	4	16
PA01	128	32	4	64	2	32
<i>Providencia stuartii</i>						
PS2636	>128	128	>1	128	4	32
NEA16	128	32	4	32	2	16
<i>Staphylococcus aureus</i>						
MRSA6	128	8	16	128	4	32
MRSA3	128	128	1	128	8	16

1: 6-C-methylquercetin-3,4'-dimethyl ether; CIP: ciprofloxacin; PA β N: phenylalanine-arginine- β -naphthylamide (an efflux pump inhibitor); Samples were tested alone or in the presence of PA β N at 20 $\mu\text{g/mL}$; Fold increase of activity was determined as the ratio of the MIC of Sample alone versus the sample in the presence of PA β N; MIC value in bold are significant antibacterial activity (Kuete, 2010).




Figure S1. UV spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S2. HRESI-MS (+) of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S3. ^1H -NMR spectrum (600 MHz, CD_3OD) of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S4. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S5. HSQC spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S6. HMBC spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S7. COSY ^1H - ^1H spectrum of 6-C-methylquercetin-3,4'-dimethyl ether (**1**)




Figure S8. ^1H -NMR spectrum (600 MHz, CD_3OD) of compound **2**




Figure S9. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of 6 compound 2




Figure S10. ^1H -NMR spectrum (600 MHz, $\text{Acetone-}d_6$) of compound 3




Figure S11. ^{13}C -NMR spectrum (150 MHz, $\text{Acetone-}d_6$) of compound 3




Figure S12. ¹H-NMR spectrum (600 MHz, Acetone-*d*₆) of compound 4




Figure S13. HMBC spectrum of compound 4




Figure S14. $^1\text{H-NMR}$ spectrum (600 MHz, $\text{DMSO-}d_6$) of compound **5**




Figure S15. $^{13}\text{C-NMR}$ spectrum (150 MHz, $\text{DMSO-}d_6$) of compound **5**




Figure S16. $^1\text{H-NMR}$ spectrum (500 MHz, CD_3OD) of compound **6**




Figure S17. ^{13}C -NMR spectrum (125 MHz, CD_3OD) of compound **6**




Figure S18. ^1H -NMR spectrum (500 MHz, CD_3OD) of compound **7**




Figure S19. ^{13}C -NMR spectrum (125 MHz, CD_3OD) of compound **7**




Figure S20. ¹H-NMR spectrum (600 MHz, DMSO-*d*₆) of compound **8**




Figure S21. ¹³C-NMR spectrum (150 MHz, DMSO-*d*₆) of compound **8**




Figure S22. ¹H-NMR spectrum (600 MHz, CD₃OD) of compound **9**




Figure S23. ^{13}C -NMR spectrum (150 MHz, CD_3OD) of compound **9**




Figure S24. ^1H -NMR spectrum (600 MHz, $\text{Acetone-}d_6$) mixture of compounds **10** and **11**




Figure S25. ^{13}C -NMR spectrum (150 MHz, $\text{Acetone-}d_6$) mixture of compounds **10** and **11**




Figure S26. ^1H -NMR spectrum (600 MHz, Pyridine- d_5) of compound **12**




Figure S27. ^{13}C -NMR spectrum (150 MHz, Pyridine- d_5) of compound **12**




Figure S28. ^1H -NMR spectrum (600 MHz, $\text{DMSO-}d_6$) of compound **13**




Figure S29. ^{13}C -NMR spectrum (150 MHz, $\text{DMSO-}d_6$) of compound **13**




Figure S30. ^1H - ^1H COSY and HMBC correlations of compound **1**.

References

Kuete V. 2010. Potential of Cameroonian plants and derived products against microbial infections: a review. *Planta Med.* 76(14):1479-1491.